The biotechnology company Bio-Works reports a sharp increase in revenue and order intake for the fourth quarter. Revenue rose 811.5 percent to 23.7 million kronor (2.6)."We have delivered strong growth, as well as a clearly improved result and cash flow. The fourth quarter is our strongest to date and clearly shows that our business model is delivering as intended and at an accelerating pace," states CEO Lone Carlbom in the report. "Revenue increased sharply both during the quarter and the full year, driven by solid demand in all regions and several larger deliveries. Order intake is at record levels and the order book at year-end gives us a stable foundation heading into 2026. Encouragingly, the operating result in the fourth quarter is approaching a positive result and that spurs us to work even harder to achieve sustainable and growing profitability within a foreseeable time," the Bio-Works chief continues. The operating result was -0.9 million kronor (-13.8). The result after tax was 1.4 million kronor (-13.2). Earnings per share amounted to 0.01 kronor (-0.17). Order intake came in at 25.6 million kronor (6.6), an increase of 287.9 percent year-on-year. Cash and cash equivalents amounted to 34.9 million kronor (34.3)."Our financial position has strengthened significantly during the year, with improved cash flow and solid liquidity. This gives us room to continue to invest selectively in growth and scaling," states Carlbom. Bio-Works, MSEKQ4-2025Q4-2024ChangeOrder intake25.66.6287.9%Net sales23.72.6811.5%Operating result-0.9-13.8Net income1.4-13.2Earnings per share, kronor0.01-0.17Cash and cash equivalents34.934.31.7%